<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INAPSINE- droperidol injection </strong><br>Akorn, Inc.<br></p></div>
<h1>Inapsine<span class="Sup">®</span><br>(Droperidol) Injection 1 mL and 2 mL
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">FOR INTRAVENOUS OR INTRAMUSCULAR USE ONLY
</p>
<p>Rx only
</p>
</div>
<div class="Warning">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>WARNING
</h1>
<p class="First"><span class="Bold">Cases of QT prolongation and/or <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> have been reported in patients receiving INAPSINE at doses at or below recommended doses. Some cases have occurred in patients with no known risk factors for QT prolongation and some cases have been fatal.</span></p>
<p>Due to its potential for serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmic effects</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, INAPSINE should be reserved for use in the treatment of patients who fail to show an acceptable response to other adequate treatments, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs (see <a href="#s7">Warnings</a>, <a href="#s21">Adverse Reactions</a>, <a href="#s6">Contraindications</a>, and <a href="#s9">Precautions</a>).
</p>
<p>Cases of QT prolongation and serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (e.g., <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>) have been reported in patients treated with INAPSINE. Based on these reports, all patients should undergo a 12-lead ECG prior to administration of INAPSINE to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males or 450 msec for females) is present. If there is a prolonged QT interval, INAPSINE should <span class="Underline">NOT</span> be administered. For patients in whom the potential benefit of INAPSINE treatment is felt to outweigh the risks of potentially serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, ECG monitoring should be performed prior to treatment and continued for 2 to 3 hours after completing treatment to monitor for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.
</p>
<p>INAPSINE is contraindicated in patients with known or suspected QT prolongation, including patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>.
</p>
<p>INAPSINE should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, use of a diuretic, <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiac hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, or administration of other drugs known to increase the QT interval). Other risk factors may include age over 65 years, <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>, and use of agents such as benzodiazepines, volatile anesthetics, and IV opiates. Droperidol should be initiated at a low dose and adjusted upward, with caution, as needed to achieve the desired effect.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">INAPSINE contains droperidol, a neuroleptic (tranquilizer) agent. INAPSINE® (droperidol) Injection is available in ampules and vials. Each milliliter contains 2.5 mg of droperidol in an aqueous solution adjusted to pH 3.4 ± 0.4 with lactic acid. Droperidol is chemically identified as l-(l-[3-(p-fluorobenzoyl) propyl]-l,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone with a molecular weight of 379.43. The structural formula of droperidol is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dbc2d9eb-eefe-454d-a8c3-55cec840d54f&amp;name=ina00-0000-01.jpg">
</div>
<p>Molecular formula: C<span class="Sub">22</span>H<span class="Sub">22</span>FN<span class="Sub">3</span>O<span class="Sub">2</span>, partition coefficient in n-octanol: water: 3.46, pKa: 7.46
</p>
<p>INAPSINE is a sterile, non-pyrogenic, aqueous solution for intravenous or intramuscular injection.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">INAPSINE (droperidol) produces marked tranquilization and sedation. It allays <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span> and provides a state of mental detachment and <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">indifference</span> while maintaining a state of reflex alertness.
</p>
<p>INAPSINE produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> during surgical procedures and provides antiemetic protection in the postoperative period.
</p>
<p>INAPSINE potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and decreased peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, but it does not prevent other <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.
</p>
<p>The onset of action of single intramuscular and intravenous doses is from three to ten minutes following administration, although the peak effect may not be apparent for up to thirty minutes. The duration of the tranquilizing and sedative effects generally is two to four hours, although alteration of alertness may persist for as long as twelve hours.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">INAPSINE (droperidol) is indicated to reduce the incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with surgical and diagnostic procedures.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s6"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">INAPSINE is contraindicated in patients with known or suspected QT prolongation (i.e., QTc interval greater than 440 msec for males or 450 msec for females). This would include patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>.
</p>
<p>INAPSINE (droperidol) is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug.
</p>
<p>INAPSINE is not recommended for any use other than for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in patients for whom other treatments are ineffective or inappropriate (see <a href="#s7">WARNINGS</a>).
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s7"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">INAPSINE should be administered with extreme caution in the presence of risk factors for development of prolonged QT syndrome, such as: 1) clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see <a href="#s13">PRECAUTIONS, Drug Interactions</a>), and 6) <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, in particular <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, or concomitant treatment with drugs (e.g., diuretics) that may cause <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-6.1"></a><p></p>
<h2>Effects on Cardiac Conduction
</h2>
<p class="First">A dose-dependent prolongation of the QT interval was observed within 10 minutes of droperidol administration in a study of 40 patients without known cardiac disease who underwent extracranial head and neck surgery. Significant QT prolongation was observed at all three dose levels evaluated, with 0.1, 0.175, and 0.25 mg/kg associated with prolongation of median QTc by 37, 44, and 59 msec, respectively.
</p>
<p>Cases of QT prolongation and serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (e.g. <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, ventricular arrythmias, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) have been observed during post-marketing treatment with INAPSINE. Some cases have occurred in patients with no known risk factors and at doses at or below recommended doses. There has been at least one case of nonfatal <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> confirmed by rechallenge.
</p>
<p>Based on these reports, all patients should undergo a 12-lead ECG prior to administration of INAPSINE to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males or 450 msec for females) is present. If there is a prolonged QT interval, INAPSINE should <span class="Bold Underline">NOT</span> be administered. For patients in whom the potential benefit of INAPSINE treatment is felt to outweigh the risks of potentially serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, ECG monitoring should be performed prior to treatment and continued for 2 to 3 hours after completing treatment to monitor for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.
</p>
<p>FLUIDS AND OTHER COUNTERMEASURES TO MANAGE <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">HYPOTENSION</span> SHOULD BE READILY AVAILABLE.
</p>
<p>As with other CNS depressant drugs, patients who have received INAPSINE (droperidol) should have appropriate surveillance.
</p>
<p>It is recommended that opioids, when required, initially be used in reduced doses.
</p>
<p>As with other neuroleptic agents, very rare reports of <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> (altered consciousness, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> and <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span>) have occurred in patients who have received INAPSINE (droperidol). Since it may be difficult to distinguish <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> from <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperpyrexia</span> in the perioperative period, prompt treatment with dantrolene should be considered if increases in temperature, heart rate or <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> production occur.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s9"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s10"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> The initial dose of INAPSINE (droperidol) should be appropriately reduced in elderly, debilitated and other poor-risk patients. The effect of the initial dose should be considered in determining incremental doses.
</p>
<p>Certain forms of conduction anesthesia, such as spinal anesthesia and some peridural anesthetics, can alter respiration by blocking intercostal nerves and can cause <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">peripheral vasodilatation</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> because of sympathetic blockade. Through other mechanisms (see <a href="#s4">CLINICAL PHARMACOLOGY</a>), INAPSINE can also alter circulation. Therefore, when INAPSINE is used to supplement these forms of anesthesia, the anesthetist should be familiar with the physiological alterations involved, and be prepared to manage them in the patients elected for these forms of anesthesia.
</p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the possibility of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> should be considered and managed with appropriate parenteral fluid therapy. Repositioning the patient to improve venous return to the heart should be considered when operative conditions permit. It should be noted that in spinal and peridural anesthesia, tilting the patient into a head-down position may result in a higher level of anesthesia than is desirable, as well as impair venous return to the heart. Care should be exercised in moving and positioning of patients because of a possibility of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>. If volume expansion with fluids plus these other countermeasures do not correct the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, then the administration of pressor agents other than epinephrine should be considered. Epinephrine may paradoxically decrease the blood pressure in patients treated with INAPSINE due to the alpha-adrenergic blocking action of INAPSINE.
</p>
<p>Since INAPSINE may decrease pulmonary arterial pressure, this fact should be considered by those who conduct diagnostic or surgical procedures where interpretation of pulmonary arterial pressure measurements might determine final management of the patient Vital signs and ECG should be monitored routinely.
</p>
<p>When the EEG is used for postoperative monitoring, it may be found that the EEG pattern returns to normal slowly.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Bold">Impaired Hepatic or Renal Function:</span> INAPSINE should be administered with caution to patients with liver and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">kidney dysfunction</span> because of the importance of these organs in the metabolism and excretion of drugs.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-7.1.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span>:</span> In patients with diagnosed/suspected pheochromocytonia, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> have been observed after the administration of INAPSINE (droperidol).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s13"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions:
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Potentially Arrhythmogenic Agents:</span> Any drug known to have the potential to prolong the QT interval should not be used together with INAPSINE. Possible <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span> can occur between INAPSINE and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants.
</p>
<p>Caution should be used when patients are taking concomitant drugs known to induce <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> as they may precipitate QT prolongation and interact with INAPSINE. These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-7.2.2"></a><p></p>
<p class="First"><span class="Bold Italics">CNS Depressant Drugs:</span> Other CNS depressant drugs (e.g., barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE. Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s16"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> No carcinogenicity studies have been carried out with INAPSINE. The micronucleus test in female rats revealed no mutagenic effects in single oral doses as high as 160 mg/kg. An oral study in rats (Segment I) revealed no impairment of fertility in either male or females at 0.63. 2.5 and 10 mg/kg doses (approximately 2.9 and 36 times maximum recommended human iv/im dosage).
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s17"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Pregnancy:</span> Category C: INAPSINE administered intravenously has been shown to cause a slight increase in mortality of the newborn rat at 4.4 times the upper human dose. At 44 times the upper human dose, mortality rate was comparable to that for control animals. Following intramuscular administration, increased mortality of the offspring at 1.8 times the upper human dose is attributed to <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> in the dams who neglected to remove placentae from their offspring. INAPSINE has not been shown to be teratogenic in animals. There are no adequate and well-controlled studies in pregnant women. INAPSINE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s18"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">Labor and Delivery:</span> There are insufficient data to support the use of INAPSINE in labor and delivery. Therefore, such use is not recommended.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s19"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> It is not known whether INAPSINE is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when INAPSINE is administered to a nursing mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s20"></a><a name="section-7.7"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> The safety of INAPSINE in children younger than two years of age has not been established.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s21"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">QT interval prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> have been reported in patients treated with INAPSINE. Some of these cases were associated with <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Some cases occurred in patients with no known risk factors, and some were associated with droperidol doses at or below recommended doses.
</p>
<p>Physicians should be alert to <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or other symptoms suggestive of episodes of irregular cardiac rhythm in patients taking INAPSINE and promptly evaluate such cases (see <a href="#s8">WARNINGS, Effects on Cardiac Conduction</a>).
</p>
<p>The most common somatic adverse reactions reported to occur with INAPSINE (droperidol) are mild to moderate <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, but these effects usually subside without treatment. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs and is severe or persists, the possibility of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> should be considered and managed with appropriate parenteral fluid therapy.
</p>
<p>The most common behavioral adverse effects of INAPSINE (droperidol) include <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, postoperative <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, which can either be the result of an inadequate dosage (lack of adequate treatment effect) or of an adverse drug reaction (part of the symptom complex of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>).
</p>
<p>Care should be taken to search for extrapyramidal signs and symptoms (<span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>) to differentiate these different clinical conditions. When <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> are the cause, they can usually be controlled with anticholinergic agents.
</p>
<p>Postoperative hallucinatory episodes (sometimes associated with transient periods of mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>) have also been reported.
</p>
<p>Other less common reported adverse reactions include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and/or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>, laryn-gospasm, and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.
</p>
<p>Elevated blood pressure, with or without pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, has been reported following administration of INAPSINE combined with SUBLIMAZE (fentanyl citrate) or other parenteral analgesics. This might be due to unexplained alterations in sympathetic activity following large doses: however, it is also frequently attributed to anesthetic or surgical stimulation during <span class="product-label-link" type="condition" conceptid="4086497" conceptname="Light anesthesia">light anesthesia</span>.
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s22"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">Manifestations: The manifestations of INAPSINE (droperidol) overdosage are an extension of its pharmacologic actions and may include QT prolongation and serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (e.g., <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>) (see <a href="#s2">BOX WARNING</a>, <a href="#s7">WARNINGS</a>, and <a href="#s9">PRECAUTIONS</a>).
</p>
<p>Treatment: In the presence of <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span> or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, oxygen should be administered and respiration should be assisted or controlled as indicated. A patent airway must be maintained; an oropharyngeal airway or endotracheal tube might be indicated. The patient should be carefully observed for 24 hours; body warmth and adequate fluid intake should be maintained. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs and is severe or persists, the possibility of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> should be considered and managed with appropriate parenteral fluid therapy (see <a href="#s9">PRECAUTIONS</a>).
</p>
<p>If significant extrapyramidal reactions occur in the context of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, an anticholinergic should be administered.
</p>
<p>The intravenous Median Lethal Dose of INAPSINE is 20 to 43 mg/kg in mice; 30 mg/kg in rats; 25 mg/kg in dogs and 11 to 13 mg/kg in rabbits. The intramuscular Median Lethal Dose of INAPSINE is 195 mg/kg in mice; 104 to 110 mg/kg in rats; 97 mg/kg in rabbits and 200 mg/kg in guinea pigs.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s23"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Dosage should be individualized.</span> Some of the factors to be considered in determining the dose are age, body weight, physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used and the surgical procedure involved.
</p>
<p>Vital signs and ECG should be monitored routinely.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-10.2"></a><p></p>
<p class="First"><span class="Bold">Adult dosage:</span> The maximum recommended initial dose of INAPSINE is 2.5 mg IM or slow IV. Additional 1.25 mg doses of INAPSINE may be administered to achieve the desired effect. However, additional doses should be administered with caution, and only if the potential benefit outweighs the potential risk.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-10.3"></a><p></p>
<p class="First"><span class="Bold">Children's dosage:</span> For children two to 12 years of age, the maximum recommended initial dose is 0.1 mg/kg. taking into account the patient's age and other clinical factors. However, additional doses should be administered with caution, and only if the potential benefit outweighs the potential risk.
</p>
<p>See <a href="#s7">WARNINGS</a> and <a href="#s9">PRECAUTIONS</a> for use of INAPSINE with other CNS depressants and in patients with altered response.
</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If such abnormalities are observed, the drug should not be administered.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s27"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">INAPSINE<span class="Sup">®</span> (droperidol) Injection is available as:
</p>
<p><span class="Bold">NDC</span> 17478-010-01, 2.5 mg/mL, 1 mL ampules in packages of 10
</p>
<p><span class="Bold">NDC</span> 17478-010-02, 2.5 mg/mL, 2 mL ampules in packages of 10
</p>
<p><span class="Bold">NDC</span> 17478-531-01, 2.5 mg/mL, 1 mL vials in packages of 25
</p>
<p><span class="Bold">NDC</span> 17478-531-02, 2.5 mg/mL, 2 mL vials in packages of 25
</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="e28"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.
</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s28"></a><a name="section-13"></a><p></p>
<h1>REFERENCES
</h1>
<ol class="Arabic">
<li>Saarnivarra L, Klemola UM, Lindgren L, et al. QT interval of the ECG, heart rate and arterial pressure using propofal, methohexital or midazolam for induction of anesthesia. Acta Anaesfhesiol Scand 1990; 34: 276-81
</li>
<li>Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by enflurane, isoflurane and halofhane in humans. Anesth Analg 1991; 72: 137-44.
</li>
<li>Spath G. Torsade des pointe oder die andere Ursache des plotz-lichen Herztodes. Wien: Ueberreuter, 1998.
</li>
<li>Riley DC, Schmeling WT, Al-Wafhiqui MH, et al. Prolongation of the QT-interval by volatile anesthetics in chronically instrumented dogs. Anesth Analg 1988; 67: 741-9.
</li>
<li>McConachie I, Keaventy JP, Healy TF, et al. Effects of anaesthesia on the QT-interval. Br J Anaesfh 1989: 63: 558-60.
</li>
<li>Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotic in the critically ill: a review of the literature. Pharmacother 1997; 17(3): 531-7.
</li>
<li>Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994; 79: 983-6.
</li>
</ol>
<p class="First"><span class="Bold">Akorn</span></p>
<p>Manufactured by: <span class="Bold">Akorn, Inc.</span></p>
<p>Lake Forest, IL 60045
</p>
<p>DPA0N    Rev. 10/11
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s29"></a><a name="section-14"></a><p></p>
<p class="First">Principal Display Panel Text for Container Label:
</p>
<p>NDC 17478-010-02
</p>
<p>Inapsine®
</p>
<p>(Droperidol) Injection
</p>
<p>5 mg/2 mL (2.5 mg/mL)
</p>
<p>For IV or IM Use
</p>
<p>Rx only 2 mL  Akorn Logo
</p>
<div class="Figure">
<a name="f02"></a><img alt="Principal Display Panel Text for Container Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dbc2d9eb-eefe-454d-a8c3-55cec840d54f&amp;name=ina00-0000-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s30"></a><a name="section-15"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 17478-010-02
</p>
<p>Inapsine®
</p>
<p>(Droperidol) Injection
</p>
<p>5 mg/2 mL (2.5 mg/mL)
</p>
<p>For Intravenous or Intramuscular Use
</p>
<p>10 Ampules (2 mL each)
</p>
<p>Rx only Not to be sold except as an unbroken box. Akorn Logo
</p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dbc2d9eb-eefe-454d-a8c3-55cec840d54f&amp;name=ina00-0000-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INAPSINE 		
					</strong><br><span class="contentTableReg">droperidol injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-010</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Droperidol</strong> (Droperidol) </td>
<td class="formItem">Droperidol</td>
<td class="formItem">2.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactic Acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-010-01</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:17478-010-02</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016796</td>
<td class="formItem">07/01/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INAPSINE 		
					</strong><br><span class="contentTableReg">droperidol injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-531</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Droperidol</strong> (Droperidol) </td>
<td class="formItem">Droperidol</td>
<td class="formItem">2.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactic Acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-531-01</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:17478-531-02</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016796</td>
<td class="formItem">07/01/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akorn, Inc.
							(062649876)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Akorn, Inc.</td>
<td class="formItem"></td>
<td class="formItem">155135783</td>
<td class="formItem">MANUFACTURE, REPACK, ANALYSIS, LABEL, PACK, RELABEL, STERILIZE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8496ebbf-5ea5-46de-b4a5-74d334d77ba7</div>
<div>Set id: dbc2d9eb-eefe-454d-a8c3-55cec840d54f</div>
<div>Version: 1</div>
<div>Effective Time: 20111222</div>
</div>
</div> <div class="DistributorName">Akorn, Inc.</div></p>
</body></html>
